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Abstract
Spinal muscular atrophy with respiratory distress (SMARD1) is an autosomal recessive neuromuscular disease caused by mutations in the IG-
HMBP2 gene, encoding the immunoglobulin l-binding protein 2, leading to motor neuron degeneration. It is a rare and fatal disease with an
early onset in infancy in the majority of the cases. The main clinical features are muscular atrophy and diaphragmatic palsy, which requires
prompt and permanent supportive ventilation. The human disease is recapitulated in the neuromuscular degeneration (nmd) mouse. No effec-
tive treatment is available yet, but novel therapeutical approaches tested on the nmd mouse, such as the use of neurotrophic factors and stem
cell therapy, have shown positive effects. Gene therapy demonstrated effectiveness in SMA, being now at the stage of clinical trial in patients
and therefore representing a possible treatment for SMARD1 as well. The significant advancement in understanding of both SMARD1 clinical
spectrum and molecular mechanisms makes ground for a rapid translation of pre-clinical therapeutic strategies in humans.
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Introduction
Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is
a form of SMA with respiratory distress because of diaphragma-
tic involvement [1, 2]. It has been recently renamed distal spinal
muscular atrophy type 1 (DSMA1 MIM#604320) and it is also known
as hereditary motor neuropathy type 6 (HMN6) [3].
It was first described by Mellins et al., in 1974 [4] who reported
two cases of newborns presenting an atypical variant of Werdnig–
Hoffmann’s disease. The main clinical feature was not muscular
weakness and hypotonia, as expected, but rather a respiratory dis-
tress, secondary to diaphragmatic insufficiency [4]. Later Bertini
et al., in 1989 [5] described this disease as a variation in infantile
SMA, characterized by a prominent involvement of diaphragm with
severe respiratory distress, and it has been recognized as a separate
clinical entity only in 1996 [6].
SMARD1 seems to be similar to SMA, but it actually differs from
a clinical and genetical point of view [3].
Its exact prevalence is not known yet, but studies have shown that
diaphragmatic palsy affects approximately 1% of patients diagnosed
with early onset SMA [7]. Ever since, more than 60 cases have been
described [8].
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SMARD1 is caused by homozygous or compound heterozygous
mutations in the immunoglobulin l-binding protein 2 (IGHMBP2)
gene located on chromosome 11q13.2-q13.4 [2]. Frameshift deletion,
inframe deletion, non-sense, splice donor-site and recessive mis-
sense mutations have been described [2].
The location and type of mutations do not appear to correlate with
the severity of clinical features [9, 10].
The result of mutations in IGHMBP2 gene is a degeneration of
motor neurons in the anterior horns, which leads to SMARD10s main
phenotypical features: irreversible diaphragmatic palsy and progres-
sive distal symmetrical muscular weakness (mainly at the lower limb
muscles). SMARD1 is considered a fatal form of infantile motor neu-
ron disease.
Life expectancy is very low, with patients dying within 13 months
and only few surviving longer [11, 12].
Clinical presentation
Respiratory distress
Respiratory distress is the main symptom of SMARD1 and it is char-
acterized by being extremely severe and rapidly progressive [3]
(Table 1). Early signs of the disease are weak cry, inspiratory stridor,
trouble eating and recurrent bronchopneumonia. The onset is often
very sudden and dramatic, needing prompt and irreversible invasive
ventilation. Unfortunately every other surgical attempt to improve the
respiratory distress, such as diaphragmatic plication, resulted to be
ineffective [3].
The cause of respiratory distress is a diaphragmatic palsy, which
usually appears within the first months of life and only in rare cases
within the first weeks. It can be seen on a chest X-ray as an abnormal
elevation of the dome of diaphragm. The eventration can affect either
one or both hemidiaphragms, but it often starts on the right side of
the chest, probably because of a pressure practiced on the diaphragm
by the liver [1, 2, 6, 7, 9].
The eventration of the diaphragm can be very suggestive for
SMARD1 when associated with one or more of the following charac-
teristics [7, 9, 13]:
 newborn with respiratory distress, eventually associated with
severe bronchopneumonia or any other kind of serious con-
dition (such as near miss sudden infant death syndrome);
 family history of a sudden and inexplicable death of a previ-
ous child;
 consanguinity in parents;
 foot and hand muscle weakness and/or distal articular retrac-
tions.
Prenatal signs
Intrauterine growth delay, prematurity and reduced foetal movements
can often be associated with SMARD1. These same non-specific
signs could be present not only in the affected patients but also in
related siblings, where they could eventually be an indication of a
form of late onset SMARD1 [9].
Neuromuscular features
Unlike every other patient with SMA, muscular weakness in patients
with SMARD1 involves the distal muscles at first and only later the
Table 1 Diagnostic criteria proposed by Pitt et al. to allow a more accurate diagnosis of SMARD1 and to help distinguish it from other
similar conditions (Pitt et al. 2003)
Clinical criteria Histopathological criteria EMG criteria
Low birth weight <3rd percentile Reduced myelinated fibre diameter
in sural nerve biopsies*
Evidence of acute or chronic
distal denervation
Onset of symptoms within the first 3 months of life Slight evidence of progressive myelinated
fibre degeneration in biopsies taken up
to 3–4 months
Evidence of significant slowing
(<70% of LLN) in one or more motor a/o
sensory nerves
Unilateral or bilateral diaphragmatic weakness No evidence of regeneration nor
demyelination, that could
justify the reduction in fibre size
Ventilator dependence within <1 month of onset
associated to inability to wean
No evidence of other dysmorphology
or other conditions
*Since the thickness of the myelin sheath is appropriate for the axon size, its reduction in diameter originates from the axon, which size is sim-
ilarly reduced.
LLN: lower limit of normal range.
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proximal ones [9, 13]. This can often be accompanied by congenital
foot deformations, which can lead to secondary finger contracture,
and fatty pads, which are deposits of adipose tissue in the proximal
phalanges [9, 13]. The reasons behind this distal muscular involve-
ment, as well as the precocious involvement of the phrenic nerve
are still unknown. It is not clear if this can be related to different
susceptibility of specific motor neuron subsets to the reduction in
IGHMBP2 protein. Moreover, SMARD1 patients typically present a
complete paralysis of the four limbs and later develop a progressive
kyphoscoliosis. In 86% of cases, deep tendon reflexes cannot be
elicited [9].
Central, sensory and autonomic nervous system
Advanced SMARD1 often presents a significant autonomic involve-
ment. Symptoms can vary from cardiac arrhythmia, to urinary
retention (with need of catheterization), bladder incontinence,
excessive sweating and constipation [9, 12]. Throughout the
course of the disease a paralysis of the hypoglossal nerve can
also be observed, which can present tongue fasciculations and
weakness of the face muscles [3]. Like in other motor neuron
diseases, in SMARD1 the oculomotor neurons seem to be spared
as well [14].
From a neurophysiological point of view, following the diagnostic
criteria defined by Pitt et al., the EMG must show an acute or chronic
distal denervation and a reduction in sensory or motor conduction
velocities (<70% of lower limit of normal range). On a sural nerve
biopsy, histopathological abnormalities are a decreased size of the
myelinated fibres, without signs of regeneration or demyelination
[15].
Juvenile SMARD1
SMARD1 has a considerable variation in onset. In the majority of
cases, there is an early onset in infancy, but many cases of juvenile
form of SMARD1 have been reported [8, 10, 13, 14, 16]. To date,
the oldest children diagnosed with SMARD1 were in their teen. An
exception is represented by a 20-year-old man that developed a dia-
phragmatic palsy and distal weakness in infancy and retained only
facial expressions and small shoulder movements by adulthood. He
also had a mild to severe cognitive impairment, which cause still
remained unclear, but it might concern the adequacy of ventilation
[8, 12].
Very recently, Hamilton and his group [17] described a case of a
21-year-old woman affected by uncomplicated SMARD1, that is, able
to work and enjoy a social life. She underwent tracheostomy very
early in her life and presented a classic distal muscle paralysis. How-
ever, she was able to complete her studies at the age of 18 and she is
currently working full-time and taking driving lessons using modified
motor vehicles.
As for the genetic aspects, the IGHMBP2 analysis revealed two
mutations, one of which has never been described before.
IGHMBP2 mutations with a Charcot-Marie-Tooth
Disease Type 2 phenotype
Cottenie et al., recently investigated an English family with two
affected siblings with clinical features consistent with a recessive
Charcot-Marie-Tooth type 2 (CMT2), whose genetic analysis revealed
compound heterozygous mutations in the IGHMBP2 gene [18].
The onset of the disease was in the late childhood, with a slow
progression: both siblings are still able to work, drive and walk with
the assistance of a walking stick and a silicon ankle foot orthosis.
Although the younger sister had a clinically milder form, they both
presented bilateral foot drop, distal weakness, upper and lower limbs
atrophy, absent reflexes, sensory loss in feet and hands, no cranial
nerve involvement and a trombone-shaped tongue. Nerve conduction
studies, as well as the sural nerve biopsy, demonstrated an axonal
neuropathy. Chest X-ray was normal and there were no respiratory
problems. This was essentially a typical form of CMT2. Using Exome
sequencing, two compound heterozygous mutations in the IGHMBP2
gene were identified: a non-sense 50 mutation and a 30 frameshift
mutation in the last exon of the gene, which mother and father were
respectively heterozygous for.
After this discovery, IGHMBP2 was Sanger sequenced in a
cohort of 85 recessive CMT2 families and 11 families turned out
with IGHMBP2 mutations. The phenotype was characterized by
childhood onset, mild glove and stocking sensory involvement and
mild sensory and motor axonal neuropathy, as demonstrated by
electrophysiological studies (velocities 40–50 m/sec., in contrast
with the severe form of SMARD1 neuropathy). Some cases pre-
sented mild scoliosis and other trombone-shaped tongues. None of
the cases had respiratory problems nor recurrent airway infections
or sleep apnoea.
Unlike patients with MFN2 mutations, the most frequent form of
CMT2, which have a near complete loss of large myelinated fibres
and widespread loss of the small ones, patients with IGHMBP2 muta-
tions have only a reduction in density of the large myelinated fibres,
while the small fibres are well preserved.
As for the protein quantification, to establish whether the abun-
dance of residual proteins correlated with the severity of the pheno-
type, IGHMBP2 was quantified in the fibroblasts and lymphoblasts of
patients with IGHMBP2-associated CMT2, SMARD1, as well as in car-
riers and controls. Results demonstrated that patient with CMT2 fea-
tures had significantly higher IGHMBP2 protein levels than SMARD1,
but lower than the controls. This indicates that clinical differences are
linked to IGHMBP2 protein levels.
Despite the reduction in protein levels, both SMARD1 and CMT2
had normal IGHMBP2-mRNA levels, suggesting that truncated or
defective proteins undergo posttranslational degradation.
IGHMBP2 protein
The IGHMBP2 gene is composed by 15 exons encoding a protein of
993 amino acids (109,149 D) [19]. The Ighmbp2 protein, also called
Immunoglobulin S-l-binding protein 2 (Slbp-2), has four domains:
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an ATPase/helicase domain, a single-stranded nucleic acid-binding
R3H domain, a DEXDc domain and an AN1-type zinc finger motif [16,
19–21]. The Ighmbp2 protein is a member of the SF1 helicase, in par-
ticular of the Upf1-like subfamily, which differs from the other mem-
bers thanks to their ability to unwind both DNA and RNA duplex in the
50?30 direction [16, 22]. Its exact function is still unknown, but it
might be involved in immunoglobulin class switching, pre-mRNA pro-
cessing events, regulation of DNA replication or interaction with TATA
binding protein [2, 23].
The Slbp-2 protein is ubiquitously expressed and in neurons it is
mainly localized in the cytoplasm, as well as in the nucleus, dendrites
and axons [24].
Despite the nearly ubiquitous expression of the gene product
Ighmbp2 (OMIM*600502), in SMARD1 the a-motoneurons are pre-
dominantly affected [19, 24].
The first report of IGHMBP2 gene mutations related to SMARD1
phenotype was published by Grohmann et al., in 2001 [2]. They
found three recessive missense mutations, two non-sense mutations,
one frameshift deletion and one splice donor mutation in six different
SMARD1 families. Moreover, Maystadt et al., identified in five
SMARD1 patients nine new mutations of this gene, in particular seven
missense and two non-sense mutations. Interestingly, seven of those
nine mutations were found at highly conserved residues of the
supposed DNA helicase domain [25].
As mentioned above, Slbp-2 has both a RH3 domain and an
ATPase/helicase domain. Fukita et al., through biochemical analysis,
demonstrated that the RH3 domain is involved in the RNA binding
process. Even if the N-terminal helicase domain alone is able to
bind RNA, it seems that RH3 domain increases this activity, allow-
ing it to operate as an ATP-dependent helicase, binding and
unwinding DNA and RNA in a sequence specific manner. In fact, a
truncation of the N-terminal sequence of the RH3 domain signifi-
cantly reduces the binding affinity both with DNA and RNA [20,
26].
The RH3 domain could be found in more than 700 proteins, with
the same structural sequences Arg-X-X-X-His and in association with
other domains, such as DEAH helicase domains, ring-type zinc fin-
gers nuclease domains and ATPase domains. Moreover, in the partic-
ular case of Slbp-2, the segment between 638 and 786 residues
where the end R3H C-terminal domain is located, binds ssDNA with
50phosphorylated guanine rich sequences and it acts as an anchor.
The N-terminal domain, on the other hand, interacts with the nucleo-
tides located downstream [20].
Although a genotype–phenotype relation has not been identified
yet, it has been observed that seven of the nine typical missense
mutations influence the ATPase activity, either through the reduction
in the structural stability or through the interference with the ATP
binding/hydrolysis of the helicase domain [16].
In particular, the T4931 mutation seems to cause a neuronal
degeneration through the reduction in intracellular Slbp-2 protein
levels [23].
In the following years, an increasing number of new mutations in
the IGHMBP2 gene have been described. Twenty-six new mutations
in the IGHMBP2 gene were reported in children who suffered from a
severe respiratory distress, because of diaphragmatic paralysis, and
from a progressive muscle weakness, which appeared within
6 months of life. Those mutations included fourteen missense, six
non-sense, four frameshift, one in-frame deletion and one frameshift
insertion [9].
Molecular features
Currently, little is known about the distribution and role of Ighmbp2 in
the pathogenesis of SMARD1. Different types of mutations have been
identified in the IGHMBP2 gene. In particular, in the neuromuscular
degeneration (nmd) mouse model an aberrant splicing near the 50
end of the gene has been detected, which comprehends 23 additional
nucleotides and a splice donor mutation (A to G) into intron 4, result-
ing in a premature stop codon. This last mutation interferes with the
normal splicing of the mRNA, causing in about 75–80% of cases a
mutation splicing and in the other 20–25% a wild-type splicing, not
only in the brain and in the spinal cord but also in all other tissues as
well [24, 27].
As mentioned above, the Ighmbp2 protein is expressed ubiqui-
tously in the organism, but, to better understand its function, it is
important to analyse the subcellular localization. For this reason
Guenther et al., investigated its localization inside the cells, through
the use of different a-Ighmbp2 antibodies in primary embryonic
mouse motor neurons, which are the first to be affected in SMARD1
[16].
The results have shown that Ighmbp2 is mostly localized in the
cytoplasm, in particular in the perinuclear cytoplasm, in the axon and
in the growth cone. Moreover, in the nmd mice it has been observed
that the expression of the protein was extremely reduced in all those
sites [16].
Another point worth considering, to further comprehend the role
of this protein, is which proteins Ighmbp2 is able to bind to. Under
this perspective, de Planell-Saguer et al., identified Reptin and Pontin,
which are two ATPase/helicases proteins, the transcription factor IIIC
220 kD (TFIIIC220) and tubulin, which are able to co-immunoprecipi-
tate with Ighmbp2. Further analysis has shown the real connection
between Ighmbp2 and both Reptin and Pontin, as well as with
TFIIIC220, but no interaction with tubulin. They also demonstrated
the ability of Ighmbp2 to bind itself [24].
Another study of the same group investigated whether Ighmbp2
was also involved in processing, regulation or metabolism of RNA,
because of its helicase domain. They observed that Ighmbp2 could
bind 3-end of both tRNAMet and tRNAArg and probably also the 50-
ends of tRNAs. These data suggested that Ighmbp2 was also able to
interact with the ribosome, but was not able to correctly translate
certain mRNAs, which are important in motor neurons nucleic acid-
binding domain [16, 24].
Overall, Ighmbp2 acts as an enzyme as well, unwinding RNA and
DNA in an ATP-dependent reaction, supporting the theory that it
shares not only sequence and structural similarities with the mem-
bers of UPF1-like helicase within superfamily1, but also its helicase
functions [16].
Moreover, Ighmbp2 is also able to hydrolyse ATP and distinguish
among NTP co-factors [16].
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Animal models
Animal models are essential to understand the basic mechanisms and
the physiology of the diseases. In particular, rodent models, natural
and transgenic, provide the opportunity to test the efficacy of poten-
tial therapies and to obtain precious information to target treatments
and improve gene and drug therapies [28–30].
Different murine models are available for motor neuron diseases
(http://www.jax.org/). The model used for SMARD1 is the nmd
mouse, in particular the B6.BKS Ighmbp2nmd-2J mouse [19, 24, 27,
29, 31–33].
As in humans, these mice present the Ighmbp2 region conserved,
even if it is located on chromosome 19 instead of chromosome 11
[29].
The nmd mouse possesses a spontaneous homozygous mutation
in the IGHMBP2 gene and develops a phenotype that is very similar to
that of SMARD1 [33]. The genetic defect consists of a single nucleo-
tide mutation (A-G) into intron 4, causing a reduction in ~80% of the
functional Ighmbp2 transcript [24, 27].
Phenotypically, homozygous mutant mice became distinguishable
from their littermate controls by the second week of age. Mutant mice
presented dorsally contracted hindlimbs and impaired locomotor
activity, and are indeed not able to stand erect [19, 27, 29, 31, 33].
The paralysis is followed by the loss of motor neuron innervation
and they usually survive only few months [24, 27, 31, 32].
The exact cause of death of affected mice is unclear, but the
inability to breathe of some of the end-stage disease animals sug-
gests that the primary cause might be the respiratory failure [27].
Pathogenesis
So far, it is unknown whether SMARD1 pathology is caused by a
defect that primarily interests motor neuron axons and endplates,
causing the cell body degeneration, or if it is because of the degenera-
tion of the motor neuron itself, resulting in the loss of the axons and
endplates [19].
The nmd mouse model can help us to better understand the
development of this disease and its pathogenesis.
Different groups have studied the relationship between Ighmbp2
mRNAs, protein levels and the nmd phenotype. Nevertheless, the lev-
els of the protein are reduced by about 20% in nmd mice, compared
to the control, while the size of the mRNA seems to be normal. It is
unclear if the protein is required only in the early-phase of the mam-
malian development and how the level of Ighmbp2 varies in the spinal
cord and motor neuron throughout all stages of life [19].
It has also been described the existence in the murine mammalian
genome of a major wild-type modifier locus on chromosome 13
(Mnm), that specifically halted motor neuron degeneration and
rescued the nmd phenotype [27].
The rescue of their phenotype, given by the introduction in trans-
genic mice of genes and t-RNAs encoded by this region, suggested
the existence of genetic modifiers of SMARD1 phenotype that were
independent from the rescue of Ighmbp2 level [25].
Another important aspect to consider is the relationship between
the time course of the motor neuron degeneration and the onset of
clinical symptoms [19]. It has been observed that, although at post-
natal day 10 the muscular strength in nmd mice is still normal, there
is already a conspicuous loss of neuron cell bodies in the lumbar
spinal cord. This demonstrates that the motor neuron loss is a very
early event in this disease, occurring even before the onset of first
clinical symptoms [19]. A possible hypothesis, supported by neuro-
pathological studies and in accordance with observations in Wallerian
degeneration, is that the motor neuron degeneration actually starts at
the spinal cord level and then travels along the axon [19]. In fact, neu-
romuscular junction denervation is a subsequent event in the
progress of the disease.
Another important aspect to consider is the difference between
clinical symptoms in SMARD1 patients and the nmd mouse model.
First of all, the onset of the diaphragmatic paralysis is an important
characteristic of the human disease, which has an early onset,
while in nmd mice the respiratory distress appears only in the late
stages [19]. Moreover, in the pathogenesis of nmd mice not only is
the motor neuron loss involved but also a progressive cardiomyop-
athy, caused by the death of the cardiomyocytes and by a func-
tional and morphological alteration of the myocardium [31]. To
investigate these aspects, Maddatu’s group created a transgenic
mouse, which expressed full length Ighmbp2 c-DNA only in the
central nervous system (CNS), including forebrain, cerebellum and
spinal cord. The results showed a sparing of the motor neurons
from the degeneration, but the life span was still significantly
diminished. In fact, this reduction in life span was because of a
congestive heart failure, caused by severe cardiomyocyte degenera-
tion [31].
Subsequently Maddatu’s group created another transgenic
mouse, able to produce a wild-type Ighmbp2 both in motor neurons
and cardiomyocytes. These mice could not be distinguished from
their siblings and the life span was extremely increased, as they lived
up to 2 years. Overall these studies showed that the nmd mice’s pre-
mature death was due also to dilated cardiomyopathy, and not only to
motor neuron degeneration [34].
A noteworthy fact is that SMARD1 patients do not develop dilated
cardiomyopathy, perhaps because they do not live long enough to
develop this kind of symptom [31, 34].
SMARD1 therapy: state of the art and
future perspectives
At the present, no effective treatment is available for SMARD1. Diag-
nosis and symptomatic therapy are delineated during the first hospi-
talization. Affected children are then usually attended by their
families, who have to face a huge care effort. Patients generally
require mechanical ventilation [8], antibiotic therapy and prophylaxis
for recurrent airway infections. Nutrition is also very important for
these patients, because of their feeding difficulty because of muscle
weakness and gastrointestinal dysfunction [35]. Moreover, physical
and occupational therapy are essential aspects of the treatment. Since
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survival rate is so low, different therapeutic approaches have recently
been evaluated, in particular gene and stem cell (SC) therapy.
Pharmacological treatment
Few pharmacological treatments have been attempted only at the pre-
clinical level in SMARD1 (Fig. 1A).
Ruiz et al., evaluated in the nmd mouse model the efficacy of a
monoclonal antibody (Mab2256) that has an agonist effect on the
tyrosine kinase receptor C (trkC), which is involved in the regulation
of neuron plasticity and synaptic strength [33, 36]. The results
showed a significant increase in muscular strength, although only
transient, a slowdown in the progression of the disease, but not its
stop, and an electrophysiological improvement of the muscular func-
tion. However, the survival probability did not show a significant
increase [33, 36].
A possible explanation of these transient effects could be that high
plasma levels of Mab2256 might suppress the expression of trkC, as
demonstrated in other studies with neurotrophins (NTs) [37, 38]. In
this case, an adjustment in the dosage of the NTs should avoid this
effect. Other possible explanations are a non-sufficient affinity/activity
of Mab2256 or that, to have clinical beneficial outcome, more NT
receptors have to be activated.
Also neurotrophic factors, such as insulin-like factor 1 (IGF1),
have been considered as a possible candidate for future treatment tri-
als, since they seem to play an important role in the pathogenesis of
SMARD1, as recently demonstrated by Krieger et al., [39]. IGF1 is a
hormone characterized by numerous functions, like muscle and neu-
ron survival or differentiation and axonal growth during development
[39]. Krieger et al., demonstrated that in the nmd model IGF1 serum
levels were quite low, supporting the hypothesis of a linkage between
IGF1 serum levels and muscular/neuronal degeneration [39]. The use
of polyethylene glycol-coupled IGF1 (PEG-IGF1) was able not only to
A
C
B
Fig. 1 (A) Pharmacological therapeutical approach for spinal muscular atrophy with respiratory distress (SMARD1): Mab2256, a monoclonal antibody
with agonist effect on the tyrosine kinase receptor C, implicated in neuron plasticity and synaptic strength; PEG-IGF1, a neurotrophic factor, which
low serum levels are likely to be linked with the muscular/neuronal degeneration. (B) Gene-therapy approach: it is based on the replacement of the
defective gene, using self-complementary adeno-associated virus vectors. (C) Stem cell-based therapeutic approach: the generation of human
induced pluripotent stem cells (iPSCs) can be obtained through the nucleofection of adult fibroblasts with constructs encoding OCT4, SOX2, NANOG,
LIN28, c-Myc and KLF4. Uncorrected SMARD1-iPSC-derived motor neurons reproduced disease-specific features, which were ameliorated in motor
neurons derived from genetically corrected SMARD1-iPSCs.iPSCs are then differentiated into neural stem cells (NSC) or GFP motorneurons and
transplanted into a SMARD1 mouse model, obtaining an improvement in the animal phenotype.
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restore the endogenous levels of IGF1 but also to reduce the core fea-
tures of the disease in the nmd mouse. This happened through two
different mechanisms: (i) increased phosphorylation of Akt (protein
kinase B) and ribosomal protein S6 kinase, which protects from mus-
cle fibre degeneration and (ii) action on sprouting of nerve terminals.
However, no significant breakthrough was made in the motor neuron
survival. A possible reason for this negative result is that the systemic
dose used in this study was not able to reach a sufficient serum con-
centration to penetrate through the blood–brain barrier, thus making
it impossible to reach an effective local tissue concentration.
Based on these findings, IGF1 and other neutrophic factors may
hold promise as candidates for future studies in SMARD1 treatment.
Gene therapy
Gene therapy has the advantage to treat the cause of the disease,
allowing the defective gene to be expressed. It is based on the utiliza-
tion of viral vectors, which carry a healthy copy of the gene into the
affected cells (Fig. 1B) [40–42]. The aim was to correct the aetiologi-
cal mechanisms underlying the clinical manifestations of the disease
[43, 44]. Many studies have been made in mouse models of SMA, a
similar genetic motor neuron disease caused by mutations in SMN1,
encouraging a future application of gene therapy also in SMARD1.
As for SMA, gene therapy mostly focuses on replacing the defec-
tive gene using self-complementary adeno-associated virus vectors
[45–48].
In fact, the discovery that the AAV9 vector was able to penetrate
the BBB allowed considering the administration of AAV by less-inva-
sive injection, such as systemic intravenous delivery and intrathecal
delivery. The administration of AAV9 encoding wild-type SMN gene
was able to rescue the phenotype of SMA mice when injected intrave-
nously [45, 46, 48]. The biodistribution of AAV in the CNS has been
replicated also in larger animals, such as non-human primates [8, 18,
49]. These positive data led to the design and approval, at the Ohio
State University, of a Phase I/II clinical trial in SMA patients using
intravenous administration and some SMA1 patients have already
been treated [50] (www.clinicaltrial.gov).
At the moment, no clinical trial with gene therapy for SMARD1
was planned.
Stem cell therapy
Currently, SCs represent a promising resource for the treatment of
neurodegenerative diseases, such as motor neuron disorders. Stem
cells are characterized by their potential to continuously renew them-
selves by symmetrical division and to originate more mature progeni-
tors of multiple lineages through asymmetrical division [51–53].
Neural stem cells (NSCs) are the precursors of the three neuroecto-
dermal lineages in the CNS. Neural stem cells transplantation can
provide positive therapeutic effects through multiple mechanisms,
including neuroprotection and cell replacement (Fig. 1C) [54, 55].
Our group previously demonstrated that murine NSC transplanted
in a SMARD1 mouse model improved the animal phenotype [56].
In our first set of experiments, we transplanted ALDH high side
scatter low (ALDHhiSSClo) NSCs in nmd mice as a possible therapeu-
tic approach for SMARD1. ALDHhiSSCloNSCs cells derived from both
embryonic and adult spinal cord and were self-renewing and multipo-
tent. They were able to differentiate into the three main lineages and
also to acquire mature complex neural phenotypes, including the
expression ofHB9/ChAT in motor neurons, in nmd mice both in vivo
and in vitro [56].
More recently, we demonstrated the therapeutic potential of more
differentiated cells, such as motor neuron precursors, transplanted
into the spinal cord of nmd mice [57].
In both cases, using NSCs or more differentiated cells, the posi-
tive effects of this approach seemed to derive more from a paracrine
effect rather than cell substitution, thanks to the production of neuro-
protective factors by induced pluripotent stem cell (iPSC)-derived
NSCs, including glial-derived neurotrophic factor, brain-derived neu-
rotrophic factor, transforming growth factor-a and NT3 [58]. In fact,
in vitro experiments demonstrated that co-culture of WT human
iPSC-derived NSCs protect human SMARD1 iPSC-derived motor neu-
rons against degeneration, probably through the production of NTs
[58].
These experiments of NSCs transplantation were performed with
primary murine NSCs. The discovery of iPSCs allowed to obtain
unlimited human cells, like NSCs, overcoming the necessity to obtain
them from CNS.
In a recent study, we demonstrated the potential therapeutical
effect that NSCs obtained from human-iPSCs could have in SMARD1.
We observed that, after being transplanted into the spinal cord of
SMARD1 animal models, NSCs were able to properly engraft and dif-
ferentiate, giving protection to their endogenous motor neurons and
therefore improving their phenotype. To evaluate the effects that
NSCs could have in the human disease, we created human SMARD1-
iPSCs motor neurons that yet presented a significantly reduced sur-
vival and a shorter axon length. The co-culture with healthy wild-type
iPSC-NSCs was able to improve the phenotype of the disease and this
amelioration can be ascribed both to the production of neurotrophic
factors and to the inhibition of Glycogen Synthase Kinase-3 (GSK-3)
and HPK1/GCK-like Kinase (HGK). These results prove that the thera-
peutical use of NSCs derived from pluripotent SCs can be considered
as a valid tool to improve SMARD1 phenotype. Another interesting
possibility is represented by the possibility to convert the disease
phenotype of iPSCs derived from SMARD1 patient in healthy iPSC
through an ex vivo gene correction and use the corrected cells as
potential autologous cell source for transplantation (Fig. 1C).
We believe that what would allow to reach a clinically significant
level in SMARD1 (and other motor neuron diseases as well) in terms
of therapeutic efficacy would be the combining of cell, drug and gene
therapy [58].
Conclusions
Musculoskeletal diseases are the second-greatest cause of disability
worldwide [59]. Unfortunately, most of these diseases are incurable.
Among those, SMARD1 is a devastating neuromuscular disease,
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which causes infantile death within 13 months of life in the majority of
the cases. Only a small number of studies described patients surviving
longer [11, 60]. It is possible indeed that an increased diffusion of next
generation sequencing as a diagnostic tool may result in an increased
rate of diagnosis, in particular of atypical phenotypes, such as long sur-
vivor patients or patients without diaphragmatic involvement.
The pathomechanisms of SMARD1, and in particular the reasons
behind the vulnerability in specific motor neuron subsets, is
unknown, but addressing this question might allow to define novel
therapeutic targets for SMARD1.
Despite the absence of a resolutive therapy, different approaches
have been tested, but only at the pre-clinical level, including, pharma-
cological treatment, gene therapy and cell therapy.
Particularly interesting appears to be the benefits observed with
neurotrophic factors, that may warrant further investigation. However,
the limit of this approach can be the difficulty in their delivery to CNS
as well as the possible systemic side effects.
Gene therapy seems one of the most appealing curative
approaches, given their translatability in human. The definition of the
therapeutic window in this case will be one of the most important
aspects. As for the cellular approach, increasing evidence suggests
that NSC transplantation can exert a therapeutic effect on motor neu-
ron disease phenotypes. Our group contributed in studying the utility
of this approach in SMARD1. Further studies need to be performed,
to define the best cell source, the modality of administration and its
safety as well as the extent of the therapeutic impact that can be
achieved with this approach.
Combinatory approaches of pharmacological, gene therapy and
cellular strategies can be envisioned of the development of effective
therapeutic strategies for SMARD1 and other genetic motor neuron
diseases.
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